Sustained therapeutic response to osimertinib treatment in metastatic pulmonary adenocarcinoma – case presentation

Maria Militaru ¹, Maria Neag ¹, Andrea Otilia Onisim ², Florentina Claudia Militaru ^{1, 2 *}

¹ Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
² Medisprof Clinic, Cluj-Napoca, Romania
* Correspondence to: Florentina Claudia Militaru, Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Hatieganu University of Medicine and Pharmacy, Marinescu Street, No. 23, 2nd floor, 400337, Cluj-Napoca, Romania. E-mail: claudiamilitaru@yahoo.com

Abstract

Metastatic non-small cell lung cancer (NSCLC) remains an incurable disease; however, the introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the results of patients with sensitizing EGFR mutations. This case presentation aims to demonstrate the therapeutic benefit of osimertinib therapy in a patient with metastatic pulmonary adenocarcinoma. This case highlights the effectiveness and long-term tolerability of first-line osimertinib in an elderly patient with metastatic disease, supporting its use in real-world clinical practice beyond controlled trial populations.